Today it was reported that the Sr VP & Chief Business Officer of MacroGenics (MGNX), Eric Blasius Risser, exercised options to buy 4,000 MGNX shares at $0.94 a share, for a total transaction value of $3,760.
Following this transaction Eric Blasius Risser’s holding in the company was increased by 33.06% to a total of $270.6K. In addition to Eric Blasius Risser, one other MGNX executive reported Buy trades in the last month.
See today’s analyst top recommended stocks >>
Based on MacroGenics’ latest earnings report for the quarter ending September 30, the company posted quarterly revenue of $20.8 million and GAAP net loss of $34.03 million. In comparison, last year the company earned revenue of $1.66 million and had a GAAP net loss of $47.04 million. Currently, MacroGenics has an average volume of 344.7K.
Based on 3 analyst ratings, the analyst consensus is Strong Buy with an average price target of $32.00, reflecting a 92.7% upside. Starting in December 2017, MGNX received 28 Buy ratings in a row. Three different firms, including BTIG and Cowen & Co., currently also have a Buy rating on the stock.
Company insider trades are published daily on the SEC (Securities and Exchange Commission). DailyInsider’s proprietary algorithm analyzes these trades and selects the most attractive stocks based on influential insider trades each day. To subscribe to the DailyInsider visit this page.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
MacroGenics, Inc. is a clinical-stage biopharmaceutical company, which engages in discovering and developing antibody-based therapeutics designed to modulate the human immune response for the treatment of cancer. Its portfolio includes Margetuximab, Flotetuzumab, MGA012, MGD013, Enoblituzumab, MGD009, and Teplizumab.
